SI2139484T1 - Postopki za zdravljenje raka s pirido pirimidin PI3K alfa inhibitorji - Google Patents

Postopki za zdravljenje raka s pirido pirimidin PI3K alfa inhibitorji

Info

Publication number
SI2139484T1
SI2139484T1 SI200831004T SI200831004T SI2139484T1 SI 2139484 T1 SI2139484 T1 SI 2139484T1 SI 200831004 T SI200831004 T SI 200831004T SI 200831004 T SI200831004 T SI 200831004T SI 2139484 T1 SI2139484 T1 SI 2139484T1
Authority
SI
Slovenia
Prior art keywords
methods
treating cancer
pi3k alpha
pyridopyrimidinone
inhibitors
Prior art date
Application number
SI200831004T
Other languages
English (en)
Inventor
Peter Lamb
David Matthews
Original Assignee
Exelixis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis, Inc. filed Critical Exelixis, Inc.
Publication of SI2139484T1 publication Critical patent/SI2139484T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SI200831004T 2007-04-10 2008-04-09 Postopki za zdravljenje raka s pirido pirimidin PI3K alfa inhibitorji SI2139484T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92289907P 2007-04-10 2007-04-10
EP08742677.1A EP2139484B9 (en) 2007-04-10 2008-04-09 Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
PCT/US2008/004573 WO2008124161A1 (en) 2007-04-10 2008-04-09 Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha

Publications (1)

Publication Number Publication Date
SI2139484T1 true SI2139484T1 (sl) 2013-10-30

Family

ID=39627802

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831004T SI2139484T1 (sl) 2007-04-10 2008-04-09 Postopki za zdravljenje raka s pirido pirimidin PI3K alfa inhibitorji

Country Status (32)

Country Link
US (1) US8513266B2 (sl)
EP (1) EP2139484B9 (sl)
JP (3) JP2010523670A (sl)
KR (1) KR101626435B1 (sl)
CN (2) CN101715345A (sl)
AU (1) AU2008236562B2 (sl)
BR (1) BRPI0810206A2 (sl)
CA (1) CA2683641C (sl)
CO (1) CO6251254A2 (sl)
CR (1) CR11100A (sl)
DK (1) DK2139484T3 (sl)
DO (1) DOP2009000243A (sl)
EA (1) EA020022B1 (sl)
EC (1) ECSP099724A (sl)
ES (1) ES2430614T3 (sl)
HK (1) HK1139863A1 (sl)
HN (1) HN2009003002A (sl)
HR (1) HRP20130688T1 (sl)
IL (1) IL201284A (sl)
MA (1) MA31358B1 (sl)
ME (1) ME00936B (sl)
MX (1) MX2009010930A (sl)
MY (1) MY150697A (sl)
NZ (1) NZ580110A (sl)
PL (1) PL2139484T3 (sl)
PT (1) PT2139484E (sl)
RS (1) RS52939B (sl)
SI (1) SI2139484T1 (sl)
TN (1) TN2009000400A1 (sl)
UA (1) UA100979C2 (sl)
WO (1) WO2008124161A1 (sl)
ZA (1) ZA200906764B (sl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
PL1940839T3 (pl) * 2005-10-07 2013-12-31 Exelixis Inc Pirydopirymidynonowe inhibitory PI3Kalfa
DK1931645T3 (da) * 2005-10-07 2014-09-29 Exelixis Inc N-(3-aminoquinoxalin-2-yl)-sulfonamidderivater og deres anvendelse som inhibitorer af phosphatidylinositol-3-kinase
CN101528231A (zh) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
DK2139484T3 (da) 2007-04-10 2013-10-21 Exelixis Inc Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa
UA98141C2 (ru) * 2007-04-11 2012-04-25 Экселиксис, Инк. Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
TW201020245A (en) 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2326628A1 (en) 2008-08-20 2011-06-01 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2326627A1 (en) 2008-08-20 2011-06-01 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020238A (en) * 2008-08-20 2010-06-01 Schering Corp Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2011100319A1 (en) 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
WO2012027536A1 (en) * 2010-08-26 2012-03-01 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
AU2011302196B2 (en) 2010-09-14 2016-04-28 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
WO2012065019A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha
WO2012158960A2 (en) * 2011-05-17 2012-11-22 H. Lee Moffitt Cancer Center & Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
WO2013015833A2 (en) * 2011-07-28 2013-01-31 Genentech, Inc Pik3ca h1047r knock-in non-human animal breast cancer model
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
AU2012332486A1 (en) 2011-11-01 2014-06-19 Arthur Decillis N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies
WO2013071264A1 (en) * 2011-11-11 2013-05-16 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CA2860051A1 (en) 2011-12-27 2013-07-04 Kadmon Corporation, Llc Methods for treatment of breast cancer nonresponsive to trastuzumab
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
US8980259B2 (en) * 2012-07-20 2015-03-17 Novartis Ag Combination therapy
KR102112885B1 (ko) 2012-08-07 2020-05-19 노파르티스 아게 B-raf 억제제, egfr 억제제 및 임의로 pi3k-알파 억제제를 포함하는 제약 조합물
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
KR20220110859A (ko) 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
UA124804C2 (uk) * 2016-08-15 2021-11-24 Пфайзер Інк. Піридопіримідинонові інгібітори cdk2/4/6
JP7027699B2 (ja) * 2017-05-09 2022-03-02 住友ゴム工業株式会社 タイヤトレッドおよびタイヤ
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
BR112022011372A2 (pt) * 2019-12-10 2022-08-23 Univ Indiana Trustees Inibidores de interação de proteína a de replicação (rpa)-dna
EP4084779A1 (en) 2019-12-30 2022-11-09 Deciphera Pharmaceuticals, LLC Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
CA3163053A1 (en) 2019-12-30 2021-07-08 Michael D. Kaufman Amorphous kinase inhibitor formulations and methods of use thereof
KR102195221B1 (ko) 2019-12-31 2020-12-24 서울대학교산학협력단 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물
CN111358952B (zh) * 2020-04-15 2022-03-15 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种抗肿瘤药物组合物及其制剂和应用
WO2023092104A1 (en) * 2021-11-18 2023-05-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
EP1521747B1 (en) * 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
WO2005082903A1 (en) 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
DE602005002562T2 (de) * 2004-05-04 2008-01-31 Warner-Lambert Company Llc Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
JP5216958B2 (ja) * 2005-07-06 2013-06-19 株式会社三和技術総合研究所 漏洩電流検出装置及び漏洩電流検出方法
PL1940839T3 (pl) * 2005-10-07 2013-12-31 Exelixis Inc Pirydopirymidynonowe inhibitory PI3Kalfa
DK1931645T3 (da) 2005-10-07 2014-09-29 Exelixis Inc N-(3-aminoquinoxalin-2-yl)-sulfonamidderivater og deres anvendelse som inhibitorer af phosphatidylinositol-3-kinase
CA2624965A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
CN101528231A (zh) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
AP2710A (en) * 2006-09-15 2013-07-30 Pfizer Prod Inc Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors
DK2139484T3 (da) 2007-04-10 2013-10-21 Exelixis Inc Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa
CA2683784A1 (en) 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido[2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
UA98141C2 (ru) 2007-04-11 2012-04-25 Экселиксис, Инк. Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
AU2008239596B2 (en) 2007-04-11 2013-08-15 Exelixis, Inc. Pyrido [2,3-D] pyrimidin-7-one compounds as inhibitors of PI3K-alpha for the treatment of cancer
TW201018685A (en) 2008-09-30 2010-05-16 Exelixis Inc Pyridopyrimidinone inhibitors of PI3Kα and mTOR

Also Published As

Publication number Publication date
HK1139863A1 (en) 2010-09-30
CN101715345A (zh) 2010-05-26
ME00936B (me) 2012-06-20
DOP2009000243A (es) 2010-10-31
PL2139484T3 (pl) 2013-12-31
KR101626435B1 (ko) 2016-06-01
US8513266B2 (en) 2013-08-20
KR20100016354A (ko) 2010-02-12
RS52939B (en) 2014-02-28
CN102727498B (zh) 2016-08-03
UA100979C2 (ru) 2013-02-25
CA2683641A1 (en) 2008-10-16
WO2008124161A1 (en) 2008-10-16
HRP20130688T1 (en) 2013-09-30
TN2009000400A1 (en) 2010-12-31
CR11100A (es) 2010-01-19
DK2139484T3 (da) 2013-10-21
EP2139484A1 (en) 2010-01-06
ECSP099724A (es) 2010-03-31
EA020022B1 (ru) 2014-08-29
IL201284A (en) 2016-06-30
CA2683641C (en) 2016-08-16
NZ580110A (en) 2012-06-29
MA31358B1 (fr) 2010-05-03
IL201284A0 (en) 2010-05-31
CO6251254A2 (es) 2011-02-21
EA200970932A1 (ru) 2010-04-30
JP2014139217A (ja) 2014-07-31
JP2010523670A (ja) 2010-07-15
AU2008236562B2 (en) 2013-11-07
JP2014034576A (ja) 2014-02-24
EP2139484B8 (en) 2013-08-21
ZA200906764B (en) 2010-08-25
PT2139484E (pt) 2013-10-31
AU2008236562A1 (en) 2008-10-16
EP2139484B1 (en) 2013-07-17
BRPI0810206A2 (pt) 2014-10-21
MY150697A (en) 2014-02-28
EP2139484B9 (en) 2014-06-11
MX2009010930A (es) 2010-01-20
CN102727498A (zh) 2012-10-17
US20100209420A1 (en) 2010-08-19
ES2430614T3 (es) 2013-11-21
HN2009003002A (es) 2014-03-24

Similar Documents

Publication Publication Date Title
HRP20130688T1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
EP1991230A4 (en) METHOD FOR THE TREATMENT OF CANCER
PT2483278E (pt) Compostos de bezoxazepina inibidores de pi3k e a sua utilização no tratamento do cancro
ZA201007524B (en) Purine pi3k inhibitor compounds and methods of use
EP2211854A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
EP2417127A4 (en) KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH THE SAME
EP2461835A4 (en) COMPOSITIONS WITH JARID1B INHIBITORS AND METHOD FOR THE TREATMENT OF CANCER
HK1216529A1 (zh) 苯並氧雜䓬 抑制劑化合物和使用方法
EP2318406A4 (en) THIOSEMICARBAZONHERMAL COMPOUNDS AND CANCER TREATMENT PROCEDURES
EP2429292A4 (en) COMPOUNDS AND COMPOSITIONS WITH CDK INHIBITORS AND METHOD FOR THE TREATMENT OF CANCER
EP2217235A4 (en) PROTEIN INHIBITORS PIM KINASES, COMPOSITIONS AND METHODS FOR TREATING CANCER
IL197315A0 (en) Treatment of cancer
ZA201006988B (en) Method and compositions for treatment of cancer
IL196208A0 (en) Methods for cancer treatment using tak1 inhibitors
EP2254411A4 (en) COMPLEMENT INHIBITORS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
IL199689A0 (en) Compounds and method for treatment of cancer
EP2176406A4 (en) COMPOSITIONS AND METHOD FOR CANCER TREATMENT
EP2295598A4 (en) METHOD AND KIT FOR DETECTING CANCER, AND THERAPEUTIC AGENT FOR CANCER
IL202307A0 (en) Multikinase inhibitors for use in the treatment of cancer
EP2242501A4 (en) THERAPEUTIC INHIBITORS OF PAI-I FUNCTION AND METHODS OF USE
EP2225226A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER
EP2117557A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF COLORECTAL CANCER
EP2214485A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP2330908A4 (en) FLUORESCENT CDK INHIBITORS FOR CANCER TREATMENT
EP2298309A4 (en) ANTITUMORAL AGENT, KIT AND METHOD FOR THE TREATMENT OF CANCER